Raashed Raziuddin is a dedicated Doctoral Student at Weill Cornell Graduate School of Medical Sciences, where he is at the forefront of innovative research in cancer nanomedicine and drug delivery systems. Currently, he is honing his expertise in targeted therapeutics within Dr. Daniel Heller’s Cancer...
Raashed Raziuddin is a dedicated Doctoral Student at Weill Cornell Graduate School of Medical Sciences, where he is at the forefront of innovative research in cancer nanomedicine and drug delivery systems. Currently, he is honing his expertise in targeted therapeutics within Dr. Daniel Heller’s Cancer Nanomedicine Lab and Jason Lewis’ Radiopharmaceuticals Lab at Memorial Sloan Kettering Cancer Center. His work focuses on leveraging standard-of-care radiation to enhance the precision of drug delivery for chemotherapeutics aimed at treating breast cancer and brain metastases. By targeting p-selectin, which is induced on the lumen of tumor blood vessels, Raashed is contributing to the development of more effective treatment modalities that minimize systemic toxicity while maximizing therapeutic efficacy.
Raashed's academic journey is bolstered by a robust foundation in biological engineering, which he is applying to the development of groundbreaking drugs, including monoclonal microbials at Evelo Biosciences. His previous experience in synthetic biology under the mentorship of Dr. Ron Weiss at MIT, alongside CRISPR research with Ailong Ke and RNA interference (RNAi) projects with Julius Lucks, has equipped him with a diverse skill set that spans bioengineering, biochemistry, and bioinformatics. Proficient in data analysis and tools such as MATLAB and ELISA, Raashed is adept at translating complex biological concepts into actionable research. His commitment to advancing cancer therapeutics through innovative engineering solutions positions him as a promising leader in the field, driven by the pursuit of knowledge and the application of cutting-edge technologies to improve patient outcomes.
